A review of aripiprazole long-acting injection

References

• Offord S, Lin J, Mirski D, Wong B. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286-97
   PubMed Web of Science ®Google Scholar
• Graffino M, Montemagni C, Mingrone C, Rocca P. Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature. Riv Psichiatr 2014;49:115-23
   PubMed Web of Science ®Google Scholar
• Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008;69:47-53
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
   PubMed Web of Science ®Google Scholar
• Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003;12:423-4
   PubMed Web of Science ®Google Scholar
• Kane JM. Improving treatment adherence in patients with schizophrenia. J Clin Psychiatry 2011;72:e28
   PubMedGoogle Scholar
• Chue P. Risperidone long-acting injection. In: Haddad P, Lambert T, Lauriello J (eds). Antipsychotic Long-Acting Injections. Oxford: Oxford University Press, 2010 Chapter 5. 93-130
   Google Scholar
• Naber D. Olanzapine pamoate for the treatment of schizophrenia. Exp Opin Pharmacother 2011;12:627-33
   PubMed Web of Science ®Google Scholar
• Chue P, Chue J. Olanzapine pamoate. Exp Opin Pharmacother 2012;13: 1661-70
   PubMed Web of Science ®Google Scholar
• Gilday E, Nasrallah HA. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev Recent Trials 2012;7:2-9
   PubMedGoogle Scholar
• Carter NJ. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia. Drugs 2012;72:1137-60
   PubMed Web of Science ®Google Scholar
• Chue P, Chue J. A review of paliperidone palmitate. Exp Rev Neurother 2012;12:1383-97
   PubMed Web of Science ®Google Scholar
• Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Sys Rev 2012;6:CD008296
   PubMed Web of Science ®Google Scholar
• Kim S, Solari H, Weiden PJ, Bishop JR. Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. Patient Prefer Adherence 2012;6:533-45
   PubMed Web of Science ®Google Scholar
• Motiwala FB, Siscoe KS, El-Mallakh RS. Review of depot aripiprazole for schizophrenia. Patient Prefer Adherence 2013;7:1181-7
   PubMed Web of Science ®Google Scholar
• Gopalakrishna G, Aggarwal A, Lauriello J. Long-acting injectable aripiprazole: how might it fit in our tool box? Clin Schizophr Relat Psychoses 2013;7:87-92
   PubMedGoogle Scholar
• Wang SM, Han C, Lee SJ, et al. Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. Neuropsychiatr Dis 2014;10:1605-11
   PubMed Web of Science ®Google Scholar
• Lincoln J. Long-acting injectable aripiprazole for adult schizophrenia. Curr Psychiatry 2013;12
   Google Scholar
• Long-acting injectable aripiprazole (Abilify Maintena) for schizophrenia. Med Lett Drugs Ther 2013;55:34-6
   Google Scholar
• Rauch AS, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27:637-652.
   Google Scholar
• Samalin L, Charpeaud T, Llorca PM. Aripiprazole long-acting for the maintenance treatment of schizophrenia. Encephale 2014;40:487-94
   PubMed Web of Science ®Google Scholar
• Shirley M, Perry CM. Aripiprazole (Abilify Maintena): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs 2014;74:1097-110
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Schizophrenia: aripiprazole prolonged-release suspension for injection. NICE Advice (ESNM39). 2014. Available at: http://www.nice.org.uk/advice/esnm39#key–points 10 March 2015
   Google Scholar
• Kahn RS, Giannopoulou A. The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Exp Rev Neurother 2015;2:1-13
   Google Scholar
• Saklad S. Texas State Department of Health Formulary Monograph Aripiprazole for Extended-Release Injectable Suspension (Aripiprazole Long-acting Antipsychotic Injection [LAI]; Abilify Maintena). 2013. Available at: http://www.dshs.state.tx.us/
   Google Scholar
• Lundbeck Canada Inc. Abilify Maintena. Product Monograph. 2014 10 March 2015
   Google Scholar
• Otsuka America Pharmaceutical Inc. Abilify Maintena. Product Monograph. 2013. Revised 6 February 2014
   Google Scholar
• Bristol-Myers Squibb. Abilify. Product Monograph. 2009. Revised 27 May 2013
   Google Scholar
• Raoufinia A, Baker RA, Eramo A, et al. Initiation of aripiprazole once-monthly in patients with schizophrenia. Curr Med Res Opin 2015;31:583-92
   PubMed Web of Science ®Google Scholar
• Simon N, Azorin JM. Rational estimation of drug dosage through pharmacometric modeling: the case of a long-acting depot antipsychotic. Encephale 2015;41:159-67
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Abilify Maintena European Public Assessment Report. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_–_Product_Information/human/002755/WC500156111.pdf 23 January 2015
   Google Scholar
• Potkin SG, Raoufinia A, Mallikaarjun S, et al. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin 2013;29:1241-51
   PubMed Web of Science ®Google Scholar
• Canadian Network for Mood and Anxiety Treatments (CANMAT) and BC Mental Health & Addiction Services (BCMHAS). Switching antipsychotic medications. Available at: http://switchrx.ca 10 March 2015
   Google Scholar
• Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014;75: 1254-60
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res 2013;150:281-8
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry 2014;205:135-44
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Baker RA, Eramo A, et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophr Res 2014;159: 415-20
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Baker RA, et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: results from two multicenter, randomized, double-blind studies. Clin Schizophr Relat Psychoses 2015;9:79-87
   PubMedGoogle Scholar
• Ishigooka J, Nakamura J, Fujii Y, et al. ALPHA Study Group. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res 2015;161:421-8
   PubMed Web of Science ®Google Scholar
• Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res 2015: 168(1-2):498-504
   Google Scholar
• Fleischhacker WW, Sanchez R, Johnson B, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol 2013;28:171-6
   PubMed Web of Science ®Google Scholar
• De Hert M, Eramo A, Landsberg W, et al. Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis. Neuropsychiatr Dis Treat 2015;11:1299-306
   PubMed Web of Science ®Google Scholar
• Thedford S. Aripiprazole Intramuscular Depot (Abilify Maintena™) Formulary Review Statewide Pharmacy and Therapeutics Committee October 18, 2013. Available at: http://www.pharmacy.umaryland.edu/programs/mhaformulary/formulary%20reviews/pdfs/2013/Aripiprazole%20ER%20injection.pdf
   Google Scholar
• Pan Mersey Area Prescribing Committee Prescribing Policy Statement Ref: Ps39. Final APC Board Date: 24 Sep 2014 Accessed 8 August 2015 https://protect-us.mimecast.com/s/Jq6kBKiAM0Z4fn http://www.panmerseyapc.nhs.uk/recommendations/documents/PS39.pdf
   Google Scholar
• Sussex Partnership NHS Foundation Trust. Aripiprazole Long-Acting Injection (Abilify Maintena) Guidelines for Prescribing and Administration. Version 3 – August 2014 Accessed 30 August 2015 https://protect-us.mimecast.com/s/X8vJBRuo7a8lT6 http://www.sussexpartnership.nhs.uk/sites/default/files/documents/aripiprazole_lai_guidelines_-_aug_14.pdf
   Google Scholar
• Scottish Medicines Consortium NHS Scotland. Aripiprazole 400mg Powder and Solvent for Prolonged Release Suspension for Injection (Abilify Maintena) SMC No. 962/14 Accessed 30 August 2015 https://protect-us.mimecast.com/s/7GwOB4hw6GvYT0 https://www.scottishmedicines.org.uk/files/advice/aripiprazole_Abilify_FINAL_April_2014_for_website.pdf
   Google Scholar
• All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2214: Aripiprazole (Abilify Maintena) 400 mg powder and solvent for prolonged release suspension for injection. July 2014 Accessed 10 August 2015 https://protect-us.mimecast.com/s/EJNGBkfm60DgfV http://www.awmsg.org/awmsgonline/app/appraisalinfo/909
   Google Scholar
• Citrome L, Kamat SA, Sapin C, et al. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. J Med Econ 2014;17:567-76
   PubMedGoogle Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ 2013;16:917-25
   PubMedGoogle Scholar
• Chue P, Chue J. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res 2012;12:259-69
   PubMed Web of Science ®Google Scholar
• Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy 2013;11:95-106
   PubMedGoogle Scholar
• Novakovic V, Adel T, Peselow E, Lindenmayer JP. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). Clin Neuropharmacol 2013;36:59-62
   PubMed Web of Science ®Google Scholar
• Kim SW, Lee YH, Jang JE, et al. Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients. Int Clin Psychopharmacol 2013;28:80-6
   PubMed Web of Science ®Google Scholar
• Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I – patient perspectives. Can J Psychiatry 2013;58(5 Suppl 1):14-22S
   Web of Science ®Google Scholar
• Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II – physician perspectives. Can J Psychiatry 2013;58(5 Suppl 1):23-9S
   Web of Science ®Google Scholar
• Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry 2014;29S2:1409-13
   Google Scholar
• Malla A, Tibbo P, Chue P, et al. Long-acting injectable antipsychotics: recommendations for clinicians. Can J Psychiatry 2013;58(5 Suppl 1):30-5S
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults. The NICE Guideline on Treatment and Management (updated edition 2014). National Clinical Guideline Number 178. National Collaborating Centre for Mental Health Commissioned by the National Institute for Heal and Care Excellence. Available at: http://www.nice.org.uk/guidance/cg178/resources/cg178–psychosis–and–schizophrenia–in–adults–full–guideline3 10 June 2015
   Google Scholar
• Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry 2015; 72:830-9
   PubMed Web of Science ®Google Scholar
• Lin X, Xu Y, Tang X, et al. A uniform ultra-small microsphere/SAIB hybrid depot with low burst release for long-term continuous drug release. Pharm Res. 2015;32(II):3708-21
   Google Scholar
• Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J. Clin Psychiatry. 2015;76(8):1085-90
   Google Scholar